Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Phage-based diagnostics
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Phage-based diagnostics
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Phage-based diagnostics and the fight against infectious disease

PBD Biotech to speak at Liverpool School of Tropical Medicine anniversary celebrations
pan North West of England’s Health and Life Sciences Cluster fight-against-infectious-disease

As the frequency of extreme events increases so does our collective vulnerability to infectious diseases such as tuberculosis, which is increasingly resistant to antibiotics and spreads during disruption, such as conflict. 2023 marks the 125th anniversary of The Liverpool School of Tropical Medicine (LSTM), an institution dedicated to supporting the tackling of infectious diseases and part of the pan North West of England’s Health and Life Sciences Cluster.

North West of England’s Health and Life Sciences Cluster

As part of the celebrations, on the 23 May a special event has been put together. Partnering with the Science and Technology Facilities Council (STFC – part of UK Research and Innovation) and the infection innovation consortium (iicon) it will look to highlight current innovation capability for tackling infectious diseases and discuss what innovations are needed in the next 25 years to better protect the global community from infectious disease.

Tuberculosis pandemic

Tuberculosis is second only to Covid as the world’s most fatal infectious disease and is increasingly resistant to antibiotics. Although often considered a problem of the global south, rates in the UK, Europe and the USA are rising . A quarter of the world’s population carry the disease, which can be activated when the individual becomes immunocompromised.

The World Health Organisation has a campaign to End TB and rapid detection and identification of the strain of mycobacteria is crucial to achieving this. Jane Theaker of clinical-stage diagnostic company PBD Biotech has been invited to the event to discuss the role of phage-based diagnostics in ending the tuberculosis pandemic.

Need for partnerships

Phil Carvil, Head of North West Clusters for STFC who is co-coordinating the event says: “The Covid pandemic has shown us the importance of partnerships in tackling major health challenges and also the need to be innovative.”

Clusters are growing mechanisms in the UK to aid this need to draw on collective expertise, knowledge, and capabilities to tackle key challenges, both within and between sectors. This event also marks the 4th anniversary of the pan North West of England’s Health and Life Sciences Cluster, which was set up to better connect this ecosystem, thereby supporting a multi-disciplinary approach to research and innovation.

He continues: “It is that connectivity between the research and innovation system which is key in order to address these global challenges. It is great to hear how companies, such as PBD Biotech are forward-thinking, looking to tackle key infectious diseases of relevance not only to the global market but also the UK. As such they have sight of current innovation capability within their target market and understand the challenges of getting novel diagnostics out into the field.”

End TB for good

Jane Theaker, CEO of PBD Biotech, comments: “Phages have multiple uses in medicine but particularly in diagnostics. As they are specific to a particular bacteria and capable of finding just a few cells of the pathogen in a blood sample, they provide a precise way to identify a disease at a very early stage of active infection. Preventative treatment can then break the cycle of infection and this will help us to End TB for good.”

The event ‘2048 – 150 Years of Infectious Disease Research and Innovation’ will take place on 23 May 2023 is jointly hosted by LSTM, iicon and STFC Register at www.eventbrite.co.uk/e/2048-150-years-of-infectious-disease-research-and-innovation-tickets-574397697977

Share:
  • Events, Press release
  • human TB, pan North West of England’s Health and Life Sciences Cluster, STFC, TB diagnostic

Related posts

Loading...
Actiphage TB diagnostic releases bacterial DNA for qPCR

16 May 2023

New Centre for Phage Research features Actiphage within Innovation Showcase

May 12, 2023
The UK’s first Centre for Phage Research is being officially launched on 16th May and featured in the UK KTN UK Phage Innovation Showcase will be Actiphage®, a phage-based molecular diagnostic for tuberculosis.
Actiphage TB diagnostic releases bacterial DNA for qPCR

16 May 2023

New Centre for Phage Research features Actiphage within Innovation Showcase

May 12, 2023
The UK’s first Centre for Phage Research is being officially launched on 16th May and featured in the UK KTN...
AACC Conference 2023 PBD booth 4578

23 - 27 July 2023

AACC Annual Scientific Meeting – Actiphage on booth 4578

April 14, 2023
The 2023 AACC Annual Scientific Meeting & Clinical Lab Expo will be an opportunity to find out more about phage-based diagnostics.
AACC Conference 2023 PBD booth 4578

23 - 27 July 2023

AACC Annual Scientific Meeting – Actiphage on booth 4578

April 14, 2023
The 2023 AACC Annual Scientific Meeting & Clinical Lab Expo will be an opportunity to find out more about phage-based...
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic tests that are urgently needed to screen LTBI and determine who will progress to active TB disease.
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic...
Actiphage TB patent extended to West Africa

Actiphage TB test patent extended to West Africa

February 24, 2023
PBD Biotech has obtained grant of its patent application for its Actiphage® incipient tuberculosis diagnostic within the regional African Intellectual Property Organization (OAPI). This covers the mainly French-speaking countries of West Africa.
Actiphage TB patent extended to West Africa

Actiphage TB test patent extended to West Africa

February 24, 2023
PBD Biotech has obtained grant of its patent application for its Actiphage® incipient tuberculosis diagnostic within the regional African Intellectual...
1 2 3 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

BIVDA member 2023
Twitter Youtube Linkedin

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house